Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

ACTIVE NOT RECRUITING Phase 2

Testing the Role of FDG-PET/CT to Predict Response to Therapy Prior to Surgery for HER2-positive Breast Cancer, The DIRECT Trial

NCT05710328 · View on ClinicalTrials.gov ↗

Study Summary

This phase II trial tests how well an imaging procedure called fludeoxyglucose F-18 (FDG) positron emission tomography/computed tomography (PET/CT) works in predicting response to standard of care chemotherapy prior to surgery in patients with HER2-positive stage IIa-IIIc breast cancer. FDG is a radioactive tracer that is given in a vein before PET/CT imaging and helps to identify areas of active cancer. PET and CT are imaging techniques that make detailed, computerized pictures of areas inside the body. The use of FDG-PET/CT may help doctors better decide if a patient needs more or less treatment before surgery in order to get the best response. This study evaluates whether FDG-PET/CT is useful in predicting a patient's response to standard of care chemotherapy.

Interventions

  • PROCEDURE Computed Tomography
  • PROCEDURE Positron Emission Tomography
  • OTHER Fludeoxyglucose F-18
  • DRUG Chemotherapy
  • PROCEDURE Surgical Procedure

Study Locations (20)

Hawaii

  • Hawaii Cancer Care Inc - Waterfront Plaza — Honolulu
  • Queen's Cancer Cenrer - POB I — Honolulu
  • Queen's Medical Center — Honolulu
  • University of Hawaii Cancer Center — Honolulu
  • Queen's Cancer Center - Kuakini — Honolulu
  • Kapiolani Medical Center for Women and Children — Honolulu
  • Castle Medical Center — Kailua
  • Wilcox Memorial Hospital and Kauai Medical Clinic — Lihue
  • Hawaii Cancer Care - Westridge — ‘Aiea

California

  • Los Angeles General Medical Center — Los Angeles
  • USC / Norris Comprehensive Cancer Center — Los Angeles
  • Saint John's Cancer Institute — Santa Monica

Illinois

  • Northwestern University — Chicago
  • Carle at The Riverfront — Danville
  • Northwestern Medicine Cancer Center Kishwaukee — DeKalb

Alabama

  • University of Alabama at Birmingham Cancer Center — Birmingham

Arizona

  • Cancer Center at Saint Joseph's — Phoenix

District of Columbia

  • Sibley Memorial Hospital — Washington D.C.

Florida

  • Mayo Clinic in Florida — Jacksonville

Idaho

  • Saint Luke's Cancer Institute - Twin Falls — Twin Falls

Trial Details

FieldValue
Enrollment Target 235 participants
Start Date 2023-05-10
Est. Completion 2029-12-31
Phase Phase 2

Sponsor

ECOG-ACRIN Cancer Research Group

52 total trials

Interested in This Trial?

Always speak with your doctor before enrolling in a clinical trial.

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT05710328

The ClinicalTrials.gov registry entry for NCT05710328 describes a study currently listed as active not recruiting. It is categorized as Phase 2, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 235 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is ECOG-ACRIN Cancer Research Group, which has 52 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.

The record links to 4 conditions, with Anatomic Stage III Breast Cancer AJCC v8 appearing as the primary indexed condition, and to 5 interventions — of which Computed Tomography is the first listed. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.

Geographic footprint matters for practical reasons: NCT05710328 reports 20 study locations spanning 8 distinct geographic areas — top geographies include Hawaii, California, Illinois. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.

Frequently Asked Questions

What is clinical trial NCT05710328 about?

NCT05710328 is a clinical study titled "Testing the Role of FDG-PET/CT to Predict Response to Therapy Prior to Surgery for HER2-positive Breast Cancer, The DIRECT Trial". This phase II trial tests how well an imaging procedure called fludeoxyglucose F-18 (FDG) positron emission tomography/computed tomography (PET/CT) works in predicting response to standard of care chemotherapy prior to surgery in patients with HER2-positive stage IIa-IIIc breast cancer. FDG is a rad...

What is the current status of trial NCT05710328?

This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 235 participants. The study started on 2023-05-10. Estimated completion is 2029-12-31.

What conditions does trial NCT05710328 study?

This clinical trial studies the following conditions: Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8, Invasive Breast Carcinoma, HER2-Positive Breast Carcinoma. These conditions were identified from the trial registry and reflect the primary focus areas of the research.

What interventions are being tested in trial NCT05710328?

The interventions under investigation include: Computed Tomography (PROCEDURE), Positron Emission Tomography (PROCEDURE), Fludeoxyglucose F-18 (OTHER), Chemotherapy (DRUG), Surgical Procedure (PROCEDURE). Each intervention is being evaluated for safety and efficacy as part of this clinical study.

Who is sponsoring clinical trial NCT05710328?

This trial is sponsored by ECOG-ACRIN Cancer Research Group, which has 52 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.

Where is trial NCT05710328 being conducted?

This trial has 20 study locations across Alabama, Arizona, California, District of Columbia, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Related

Data sourced from official U.S. government datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial